American biopharmaceutical company in Boston, Massachusetts, founded in 1998 and listed on the Nasdaq, which works in gastrointestinal health. Sells linaclotide, marketed as Linzess in the United States, for irritable bowel syndrome with constipation and chronic idiopathic constipation, develops apraglutide and other treatments for short bowel syndrome and further gastrointestinal conditions, and spun out its central nervous system work as Cyclerion Therapeutics in 2019.
コメントはありません。
評価とコメントを残す